Literature DB >> 30841008

Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019.

Pedro Pimentel-Nunes1,2,3, Diogo Libânio1,2, Ricardo Marcos-Pinto2,4, Miguel Areia2,5, Marcis Leja6, Gianluca Esposito7, Monica Garrido4, Ilze Kikuste6, Francis Megraud8, Tamara Matysiak-Budnik9, Bruno Annibale7, Jean-Marc Dumonceau10, Rita Barros11,12, Jean-François Fléjou13, Fátima Carneiro11,12,14, Jeanin E van Hooft15, Ernst J Kuipers16, Mario Dinis-Ribeiro1,2.   

Abstract

Patients with chronic atrophic gastritis or intestinal metaplasia (IM) are at risk for gastric adenocarcinoma. This underscores the importance of diagnosis and risk stratification for these patients. High definition endoscopy with chromoendoscopy (CE) is better than high definition white-light endoscopy alone for this purpose. Virtual CE can guide biopsies for staging atrophic and metaplastic changes and can target neoplastic lesions. Biopsies should be taken from at least two topographic sites (antrum and corpus) and labelled in two separate vials. For patients with mild to moderate atrophy restricted to the antrum there is no evidence to recommend surveillance. In patients with IM at a single location but with a family history of gastric cancer, incomplete IM, or persistent Helicobacter pylori gastritis, endoscopic surveillance with CE and guided biopsies may be considered in 3 years. Patients with advanced stages of atrophic gastritis should be followed up with a high quality endoscopy every 3 years. In patients with dysplasia, in the absence of an endoscopically defined lesion, immediate high quality endoscopic reassessment with CE is recommended. Patients with an endoscopically visible lesion harboring low or high grade dysplasia or carcinoma should undergo staging and treatment. H. pylori eradication heals nonatrophic chronic gastritis, may lead to regression of atrophic gastritis, and reduces the risk of gastric cancer in patients with these conditions, and it is recommended. H. pylori eradication is also recommended for patients with neoplasia after endoscopic therapy. In intermediate to high risk regions, identification and surveillance of patients with precancerous gastric conditions is cost-effective. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2019        PMID: 30841008     DOI: 10.1055/a-0859-1883

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  143 in total

Review 1.  Recent Guidelines on the Management of Patients with Gastric Atrophy: Common Points and Controversies.

Authors:  Tamara Matysiak-Budnik; Maria Constanza Camargo; Maria Blanca Piazuelo; Marcis Leja
Journal:  Dig Dis Sci       Date:  2020-07       Impact factor: 3.199

Review 2.  Endoscopic Upper GI Screening.

Authors:  Alanna Ebigbo; Helmut Messmann; Christoph Römmele
Journal:  Visc Med       Date:  2019-07-25

Review 3.  Diagnosis: gastric intestinal metaplasia - what to do next?

Authors:  David Y Graham; Massimo Rugge; Robert M Genta
Journal:  Curr Opin Gastroenterol       Date:  2019-11       Impact factor: 3.287

Review 4.  What is the Relevance of Gastric Microbiota Beyond H. pylori?

Authors:  Kerstin Schütte; Peter Malfertheiner; Christian Schulz
Journal:  Curr Treat Options Gastroenterol       Date:  2019-12

Review 5.  Role of TFF3 as an adjunct in the diagnosis of Barrett's esophagus using a minimally invasive esophageal sampling device-The CytospongeTM.

Authors:  Anna L Paterson; Marcel Gehrung; Rebecca C Fitzgerald; Maria O'Donovan
Journal:  Diagn Cytopathol       Date:  2019-12-09       Impact factor: 1.582

6.  AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia.

Authors:  Samir Gupta; Dan Li; Hashem B El Serag; Perica Davitkov; Osama Altayar; Shahnaz Sultan; Yngve Falck-Ytter; Reem A Mustafa
Journal:  Gastroenterology       Date:  2019-12-06       Impact factor: 22.682

7.  Graves' disease patients with iron deficiency anemia: serologic evidence of co-existent autoimmune gastritis.

Authors:  Andrew G Gianoukakis; Shelly Gupta; Theresa N Tran; Patrick Richards; Marelle Yehuda; Sarah E Tomassetti
Journal:  Am J Blood Res       Date:  2021-06-15

Review 8.  Histologic Subtyping of Gastric Intestinal Metaplasia: Overview and Considerations for Clinical Practice.

Authors:  Shailja C Shah; Andrew J Gawron; Reem A Mustafa; M Blanca Piazuelo
Journal:  Gastroenterology       Date:  2019-12-06       Impact factor: 22.682

9.  Clinicopathologic Characteristics of Patients with Gastric Superficial Neoplasia and Risk Factors for Multiple Lesions after Endoscopic Submucosal Dissection in a Western Country.

Authors:  Gisela Brito-Gonçalves; Diogo Libânio; Pedro Marcos; Inês Pita; Rui Castro; Inês Sá; Mário Dinis-Ribeiro; Pedro Pimentel-Nunes
Journal:  GE Port J Gastroenterol       Date:  2019-09-03

10.  Prevalence of Gastric Intestinal Metaplasia in a Multiethnic US Veterans Population.

Authors:  Theresa H Nguyen; Mimi C Tan; Yan Liu; Massimo Rugge; Aaron P Thrift; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2020-03-14       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.